Correction to: Galcanezumab in episodic migraine: subgroup analyses of efficacy by high versus low frequency of migraine headaches in phase 3 studies (EVOLVE-1

Overview of attention for article published in The Journal of Headache and Pain, December 2019

Altmetric Badge

About this Attention Score

Good Attention Score compared to outputs of the same age (65th percentile)
Above-average Attention Score compared to outputs of the same age and source (64th percentile)

Mentioned by

policy: 1 policy source

twitter: 1 X user

Citations

dimensions_citation: 4 Dimensions

Readers on

mendeley: 19 Mendeley

Summary Policy documents X Dimensions citations

So far, Altmetric has seen 1 policy document that references this research output.

galcanezumab

Cited by Canadian Agency for Drugs and Technologies in Health on 28 Feb 2022

CADTH is an independent, not-for-profit organization responsible for providing health care decision-makers with objective evidence to help make informed decisions about the optimal use of health technologies.

This page shows the most recent policy documents that mention this research output.

Click here to find out how to access more activity.